Biotin-Protein L

Protein L is a cell surface protein from Peptostreptoccocus magnus that binds to the variable light chains (kappa chain) of immunoglobulins without interfering with antigen binding. In contrast to IgG-binding proteins, such as protein A and protein G, protein L can be used for the detection and purification of mammalian kappa light chain antibodies of all classes. Biotin-Protein L, which is produced by covalently linking biotin to protein L, can be used in immunodetections, such as immunoblotting (western or dot blot), ELISA, and immunohistochemistry.

价格	￥980 在线订购包邮(港澳台除外)
产品编号	M00097
规格	1 mg 大单询价
数量
参考货期


咨询产品问题

应用指导产品属性图例技术背景有限使用许可与使用限制

应用指导

Working concentrations for specific applications should be determined by titration assay. The chart below may serve as a useful guideline, but primary antibody, temperature, incubation time, the amount of antigen, and the sensitivity of the detection methods can all affect the ideal working concentration.

Application	Recommended Usage
Dot blot	1:2,000-1:20,000
Western blot	1:2,000-1:20,000
ELISA	1:20,000-1:100,000
Other applications	user-optimized

产品属性

Concentration	1 mg/ml, lyophilized with PBS, pH 7.4, containing 1% BSA and 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized product with deionized water (or equivalent) to the final concentration of 1.0 mg/ml.
Storage	The product remains stable in lyophilized form for 1 year if stored at 2-8°C, -20°C, or lower from the date of receipt. For longer storage, -20°C or below is recommended. The reconstituted product can be stored for 2-3 weeks at 2-8°C or for 1 year at -20°C or below. Avoid repeated freezing and thawing cycles.

图例

技术背景

Target Background

有限使用许可与使用限制

有限使用许可与使用限制

This Product is provided under a limited, non-exclusive, non-transferable, and non-sublicensable end-user license strictly limited to the permitted uses set forth in GenScript’s official documentation, quotations, or written agreements. Any use beyond such scope requires GenScript’s prior written authorization or license.
Except as expressly authorized in writing by GenScript, Customer shall not, and shall not permit, procure, enable, or assist any third party to: (a) commercialize or otherwise exploit the Product, including by reselling, distributing, transferring, sublicensing, or otherwise making the Product (including any product incorporating the Product) available to any third party; (b) copy, reproduce, clone, reverse clone, sequence, analyze, characterize, deconstruct, reconstruct, reverse engineer, or otherwise attempt to discover the composition, sequence, structure, binding characteristics, epitope recognition characteristics, or other proprietary features of the Product; (c) modify, derivatize, humanize, optimize, mutate, design around, or generate any variants, derivatives, fragments, substitutes, or functional equivalents of the Product; or (d) use the Product, any information derived therefrom, or any computational, AI-enabled, or sequence-based design method to develop, manufacture, offer for sale, sell, or commercialize any product or service competitive with the Product or GenScript’s products or services.
All intellectual property rights and all rights not expressly granted herein are reserved by GenScript. No rights are granted by implication, estoppel, or otherwise.

For research use only. Not intended for human and animal therapeutic or diagnostic use.

相关文献

1. Xianjun Li, et al. Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy. Nature biomedical engineering. (2026-04)
2. Edward Z Song, et al. Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma. Nature Communications. (2025-11)
3. Shin-Ichiro Takayanagi, et al. A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism. Commun Biol. (2024-06)
4. Gerard J Chu, et al. The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation. Cancer Cell Int. (2023-12)
5. Carbonneau S, et al. An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell chemical biology. (2020-12)
6. Cui J, et al. Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. Cancers (Basel). (2020)
7. Yu Ping, et al. Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. Front Cell Dev Biol. (2020)
8. Teilo H Schaller, et al. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. J Immunother Cancer. (2020)
9. Daria A, et al. Analysis of in vitro activity of PSCA-specific CARs in the context of human NK cell line YT. Cellular Therapy and Transplantation. (2018-07)
10. Daria A. Matvienko , et al. Analysis of in vitro activity of PSCA-specific CARs in the context of human NK cell line YT. Cellular Therapy and Transplantation (CTT). . (2018-07)
11. Andrijauskaite K, et al. IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells. Cancer Gene Ther. (2015-07)